Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle™ nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics, addressing a significant challenge in drug delivery.
The Deciparticle™ platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. By reducing particle size to below 20 nanometers, the platform aims to improve drug solubility, enhance bioavailability, and potentially reduce toxicity compared to conventional formulations. This technology is particularly relevant for drugs that are poorly water-soluble, a common issue in oncology that limits the use of effective therapeutic agents.
The companies plan to showcase development progress across multiple Deciparticle™ programs. Among these is Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation. Traditional docetaxel formulations often require polysorbate 80, which can cause hypersensitivity reactions; eliminating this excipient could improve patient safety. Another program, Sapu003, is an intravenous everolimus nanomedicine currently in a global Phase 1b clinical trial. Everolimus, an mTOR inhibitor, has limited water solubility, and the nanoparticle formulation may enhance its therapeutic index.
The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI™ platform. This AI-enabled system supports research, biomarker discovery, and regulatory processes by analyzing large datasets, potentially accelerating the development of new nanomedicine candidates.
The significance of this announcement lies in the potential of the Deciparticle™ platform to overcome long-standing barriers in drug delivery. Many potent anticancer drugs are hydrophobic, making them difficult to administer intravenously without using toxic solvents or complex formulations. The ability to form stable nanoparticles under 20 nanometers could allow for more efficient drug targeting, improved pharmacokinetics, and reduced side effects. Additionally, the use of AI in formulation development may streamline the identification of optimal drug-polymer combinations, reducing the time and cost of bringing new therapies to patients.
The BIO International Convention is a major industry event, and presenting at this forum provides visibility for the platform and its pipeline. For Oncotelic Therapeutics, which focuses on oncology and rare pediatric indications, and Sapu Nano, a company dedicated to next-generation nanomedicine, this presentation underscores their commitment to innovation in drug delivery. The collaboration between the two entities leverages Oncotelic’s drug development expertise and Sapu Nano’s platform technology.
For more information, the full press release is available at https://ibn.fm/RUG7m. About Oncotelic Therapeutics: It is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. About Sapu Nano: It is a biotechnology company developing nanomedicine platforms. Further details on Oncotelic can be found at https://ibn.fm/OTLC.
